Dan Estes

Dr. Dan Estes is a General Partner on the Frazier Life Sciences team and focuses on company formation and investments in private biopharmaceutical companies. He has been a co-founder of seven companies, including Arcutis (NASDAQ: ARQT), Lengo Therapeutics and Sudo Biosciences, and currently serves on the board of directors of Inipharm, Cirius Therapeutics, and Hawkeye Therapeutics. He previously served on the boards of Semnur Pharmaceuticals (acquired by Scilex), Arcutis (NASDAQ: ARQT), and Sierra Oncology (NASDAQ: SRRA), and led Frazier’s investment in Tarsus Pharmaceuticals (NASDAQ: TARS). He has also been involved with Frazier’s investments in Acerta Pharma BV (acquired by AstraZeneca), Tobira Therapeutics (acquired by Allergan), Ignyta (acquired by Roche), Iovance (NASDAQ: IOVA), Vaxcyte (NADAQ: PCVX), and PreCision Dermatology (acquired by Valeant).